Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data
In patients at high risk for severe COVID-19, the benefits of early sotrovimab treatment may extend beyond the acute phase of COVID-19 and contribute to the prevention of PASC symptoms.
Authors
- Tracy Guo
- Myriam Gharbi (ORCID: https://orcid.org/0000-0002-8994-2816)
- Helen J. Birch (ORCID: https://orcid.org/0000-0002-4924-4810)
- Maral DerSarkissian (ORCID: https://orcid.org/0000-0002-5528-6531)
- Daisy Liu (ORCID: https://orcid.org/0000-0002-2970-4357)
- Mei Sheng Duh (ORCID: https://orcid.org/0000-0001-5035-6687)
- Iain Gillespie (ORCID: https://orcid.org/0000-0002-2265-9506)
- Jennifer Han (ORCID: https://orcid.org/0000-0003-4744-8067)
- Catherine Sharpe (ORCID: https://orcid.org/0000-0003-0704-3380)
- Sunil Kalia (ORCID: https://orcid.org/0000-0002-5271-5273)
- Melissa Van Dyke
- Rose Chang
Institutions
- GlaxoSmithKline (United States) (US)
- Geotechnical Consulting Group (United Kingdom) (GB)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Infection
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1007/s15010-025-02505-z
- Citations
- 1
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 1.39